Novo Nordisk A/S has grown revenue 20% a year over three years and 19% a year over five, with earnings per share compounding at 24%. Revenue growth, 3-year annual rate: +20% (Drug Manufacturers - General median +6.3%). Revenue growth, 5-year rate: +19%, growth has picked up over the last three years. Earnings per share, 3-year rate: +24%, earnings outgrew revenue: margins or the share count worked for shareholders. Years of annual history on file: 11, FY2015 to FY2025, as filed.

NVONovo Nordisk A/S

Healthcare

$38.62-35% 1Y

$38.62

$34.7652 weeks$61.72

Is it growing?

Mixed

Neither accelerating nor breaking down: revenue roughly flat (+6% year on year) and earnings roughly flat (+2% year on year).

3 neutral

Revenue trend+6% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +19% a year.

Earnings trend+2% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction−0.3 points operating

Trailing-twelve-month operating margin, 41.3% now against 41.7% a year earlier.

All from SEC EDGAR, as of Dec 31, 2025.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is NVO growing?

Novo Nordisk A/S has grown revenue 20% a year over three years and 19% a year over five, with earnings per share compounding at 24%.

+20%

Revenue growth, 3-year annual rate · Drug Manufacturers - General median +6.3% · compounding fast · compounded from fiscal years as filed

Revenue growth, 5-year rate: +19%
Revenue growth, 5-year rate · +20% over three · growth has picked up over the last three years
Earnings per share, 3-year rate: +24%
Earnings per share, 3-year rate · revenue +20% · earnings outgrew revenue: margins or the share count worked for shareholders
Years of annual history on file: 11
Years of annual history on file · FY2015 to FY2025, as filed